Research programme: therapeutic cancer vaccines - IRX TherapeuticsAlternative Names: IRX 4; IRX 5; IRX 6
Latest Information Update: 17 Jun 2010
At a glance
- Originator IRX Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jun 2010 IRX Therapeutics raises $US8 million in funds through a note offering to existing shareholders; funds will be used to further develop the company's cancer vaccine programmes
- 28 May 2007 Preclinical trials in Cancer in USA (unspecified route)